赞布替尼与抗MAG神经病变 (MAZINGA)
扎努布替尼,一种第二代BTK抑制剂,用于抗MAG抗体神经病变:意大利多中心二期临床试验(MAZINGA)
The MAZINGA study is a multicenter, open-label, single-arm Phase IIA clinical trial designed to evaluate the efficacy, safety, and tolerability of zanubrutinib in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) antibody-associated demyelinating polyneuropathy. Anti-MAG neuropathy is a rare immune-mediated disorder frequently associated with IgM monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia, and other indolent B-cell lymphoproliferative disorders.
The primary objective of the study is to determine whether 12 months of treatment with zanubrutinib leads to a clinically meaningful neurological improvement, defined as an improvement of at least one point in at least two validated neurological scales. These include reductions in the Overall Neuropathy Limitations Scale (ONLS), INCAT Disability Score, and INCAT Sensory Sum Score (ISS), along with increases in the Medical Research Council (MRC) sum score and the I-RODS functional score.
Secondary objectives include the evaluation of neurophysiological improvement assessed by nerve conduction studies (ENG/EMG), particularly changes in distal motor latency, terminal latency index, and sensory action potential amplitude at 12, 24, and 48 months. Additional secondary endpoints assess hematological efficacy through overall response rate (complete response, very good partial response, or partial response), event-free survival, time to neurological progression, and overall survival. The safety profile of zanubrutinib will be characterized by the incidence, type, and severity of adverse events, serious adverse events, and events of special interest.
Eligible participants are adults (≥18 years) with a confirmed diagnosis of anti-MAG IgM-associated demyelinating polyneuropathy, evidence of a relevant IgM monoclonal gammopathy, elevated anti-MAG antibody titers, and measurable neurological disability. Both treatment-naïve and relapsed/refractory patients are eligible. Key exclusion criteria include prior treatment with BTK inhibitors, aggressive lymphomas, significant axonal damage, uncontrolled comorbidities, active infections, pregnancy, or conditions that could interfere with study participation or safety evaluation.
The planned sample size is approximately 50 patients recruited from nine Italian centers. Statistical analyses will compare neurological outcomes with historical controls, estimate survival endpoints using Kaplan-Meier methods, and explore associations between clinical outcomes and molecular features. This study aims to provide robust prospective evidence on the role of BTK inhibition in anti-MAG neuropathy and to inform future therapeutic strategies for this rare and disabling condition.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Andrea Visentin, Dr, Medical Doctor
- 电话号码:+39 049 821 2298
- 邮箱:ANDREA.VISENTIN@UNIPD.IT
研究联系人备份
- 姓名:Manuela Taurisano, Pharmacy, PhD
- 电话号码:+39 3513590476
- 邮箱:mtaurisano@clinopshub.com
学习地点
-
-
Milan
-
Milan、Milan、意大利、20162
- 招聘中
- CTU Ematologia, Grande Ospedale Metropolitano Niguarda
-
首席研究员:
- Anna Maria Frustaci, MD
-
接触:
- Anna Maria Frustaci, MD, Medical Degree (Hematology)
- 电话号码:+390264442668
- 邮箱:annamaria.frustaci@ospedaleniguarda.it
-
接触:
- Lucia Bacigaluppi
- 电话号码:+390264447597
- 邮箱:lucia.bacigaluppi@ospedaleniguarda.it
-
Milan、Milan、意大利、20089
- 招聘中
- Neuroimmunology and neuromuscular disease unit, IRCCS Ospedale Clinico Humanitas di Rozzano, Milano
-
接触:
- Pietro Emiliano Doneddu, MD, Medical Degree (Neurology)
- 电话号码:(+39) 0282247761
- 邮箱:pietro.doneddu@hunimed.eu
-
-
PD
-
Padova、PD、意大利、35128
- 招聘中
- UOC Ematologia, Azienda Ospedale Università Padova
-
首席研究员:
- Andrea Visentin, MD
-
接触:
- Andrea Visentin, MD, Medical Degree (Hematology)
- 电话号码:+39 049 821 2298
- 邮箱:andrea.visentin@aopd.veneto.it
-
-
PV
-
Pavia、PV、意大利、27100
- 招聘中
- SC Ematologia 1 - Fondazione IRCCS Policlinico San Matteo
-
接触:
- Martina La Fauci
- 电话号码:+39 0382503084
- 邮箱:cto-oh@smatteo.pv.it
-
首席研究员:
- Marzia Varettoni, MD
-
-
RM
-
Roma、RM、意大利、00168
- 招聘中
- UOSD Leucemia Linfatica Cronica, Fondazione Policlinico Universitario "A. Gemelli", IRCCS
-
接触:
- Florenzia Vuono
- 电话号码:+39 0630157833
- 邮箱:florenzia.vuono@policlinicogemelli.it
-
首席研究员:
- Luca Laurenti, MD
-
-
TO
-
Torino、TO、意大利、10126
- 招聘中
- SC Ematologia U, Ospedale Molinette, Torino (TO)
-
接触:
- Simone Ferrero, MD, Medical Degree (Hematology)
- 电话号码:+39 0116334220
- 邮箱:simone.ferrero@unito.it
-
-
Trieste
-
Trieste、Trieste、意大利、34129
- 招聘中
- SC UCO Ematologia, Ospedale Maggiore di Trieste
-
首席研究员:
- Francesco Zaja, MD
-
接触:
- Francesco Zaja, Prof., Medical Degree (Hematology)
- 电话号码:+390403992015
- 邮箱:francesco.zaja@asugi.sanita.fvg.it
-
接触:
- Maria Chiara Rossetti
- 电话号码:+ 390403992897
- 邮箱:mariachiara.rossetti@asugi.sanita.fvg.it
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria (MAIN):
- age ≥18 years;
- diagnosis of anti-MAG antibody polyneuropathy;
- neurophysiological (ENG/EMG) evidence of a demyelinating polyneuropathy with evidence of disproportionately prolonged distal motor latency in one or more nerves -excluding the median nerve if related to carpal tunnel syndrome
- IgM monoclonal protein underlying MGUS (based on the WHO definition of clonal lympho- plasmocytes <10%), Waldenstrom macroglobulinemia (based on the WHO definition of clonal lympho-plasmocytes ≥10%), marginal zone lymphoma, chronic lymphocytic leukemia or low- grade lymphoma not otherwise specified;
- presence of anti MAG antibodies (titer ≥ 7.000 BTU);
- neurophysiological (ENG/EMG) evidence of demyelinating polyneuropathy.
Exclusion Criteria (MAIN):
- Previous treatment with BTK inhibitors
- Aggressive non-Hodgkin lymphoma or IgM multiple myeloma
- Evidence of moderate or severe motor nerve axonal damage, defined when occurring diffuse polyneuropathic denervation or a recruitment pattern lower than intermediate in ≥50% of muscles examined, and/or INCAT at lower limbs ≥4.
- ECOG >3
- Use of strong CYP3A inducers within 14 days prior to the first dose of zanubrutinib
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment arm
Zanubrutinib |
ZANUBRUTINIB ORAL CAPSULES or Brukinsa Oral Capsule |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
定义为在泽布替尼治疗12个月后至少改善1分的患者中神经系统改善的比例。
大体时间:5年
|
5年
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- MAZ-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.